Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
Only one large scale cardiovascular outcome study has been completed and published for the thiazolidines-iones in type 2 diabetes, the PROactive study which demonstrates a strong trend in favour of a specific cardioprotective effect of pioglitazone. The other available data, published as meta-analyses, suggest that there is a difference in this regard between pioglitazone and rosiglitazone.